Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorBESTARD, O.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorKAMINSKI, Hannah
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorCOUZI, Lionel
dc.contributor.authorFERNÁNDEZ-RUIZ, M.
dc.contributor.authorMANUEL, O.
dc.date.accessioned2024-09-26T08:38:49Z
dc.date.available2024-09-26T08:38:49Z
dc.date.issued2023
dc.identifier.issn0934-0874en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/201838
dc.description.abstractEnUtilizing assays that assess specific T-cell-mediated immunity against cytomegalovirus (CMV) holds the potential to enhance personalized strategies aimed at preventing and treating CMV in organ transplantation. This includes improved risk stratification during transplantation compared to relying solely on CMV serostatus, as well as determining the optimal duration of antiviral prophylaxis, deciding on antiviral therapy when asymptomatic replication occurs, and estimating the risk of recurrence. In this review, we initially provide an overlook of the current concepts into the immune control of CMV after transplantation. We then summarize the existent literature on the clinical experience of the use of immune monitoring in organ transplantation, with a particular interest on the outcomes of interventional trials. Current evidence indicates that cell-mediated immune assays are helpful in identifying patients at low risk for replication for whom preventive measures against CMV can be safely withheld. As more data accumulates from these and other clinical scenarios, it is foreseeable that these assays will likely become part of the routine clinical practice in organ transplantation.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enImmune monitoring
dc.subject.enCytomegalovirus management
dc.subject.enInnate immunity
dc.subject.enPreventive strategies
dc.subject.enAntiviral prophylaxis
dc.title.enCytomegalovirus Cell-Mediated Immunity: Ready for Routine Use?
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/ti.2023.11963en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
bordeaux.journalTransplant Internationalen_US
bordeaux.volume36en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04710139
hal.version1
hal.date.transferred2024-09-26T08:38:52Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Transplant%20International&rft.date=2023&rft.volume=36&rft.eissn=0934-0874&rft.issn=0934-0874&rft.au=BESTARD,%20O.&KAMINSKI,%20Hannah&COUZI,%20Lionel&FERN%C3%81NDEZ-RUIZ,%20M.&MANUEL,%20O.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée